Since 1989, we’ve been improving the quality of health care for Rwandans.
- More than 305,000 men and boys have received voluntary medical male circumcision services, thereby benefiting from this procedure’s protective effect against HIV infection.
- The Government of Rwanda formally adopted a Jhpiego-developed quality assurance tool designed to improve the quality of care provided by health care workers to victims of gender-based violence.
- Introduction of postpartum family planning (PPFP) services in 10 districts led to the Rwandan Ministry of Health adopting and prioritizing PPFP in all districts.
- The use of data “dashboards” at health care facilities has led to improvements in quality of care and increased access to services. At one Jhpiego-supported facility in Nyaruguru District, for example, this innovation led to a 50% increase in the number of pregnant women attending all four recommended antenatal care visits.
Our Work in Rwanda
With funding from the U.S. Department of Defense, Jhpiego is supporting the Rwandan Defense Forces (RDF) to scale up voluntary medical male circumcision (VMMC) services. This project aims to: 1) increase circumcision coverage among military personnel by strengthening VMMC services within RDF’s health services; and 2) reduce the number of new HIV infections and other sexually transmitted infections among military members, their families and the surrounding civilian communities.
Impact Malaria is a global project of the U.S. President’s Malaria Initiative to reduce mortality and morbidity caused by malaria. Implemented by a consortium of organizations led by PSI, the project is funded by the U.S. Agency for International Development. In close collaboration with Rwanda’s National Malaria Control Program, other sections of the Ministry of Health and various implementing partners, Impact Malaria is designed to improve malaria service delivery via the following objectives: 1) improve the quality of and access to malaria case management and prevention of malaria in pregnancy; 2) improve the quality of and access to other malaria drug-based approaches and provide support to pilot/scale up newer malaria drug-based approaches; and 3) provide global technical leadership, support operational research and advance program learning.